Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a concise review of medically important applications of Human Leukocyte Antigen (HLA) in medicine. It covers both basic knowledge of HLA and its main clinical applications in medical practice. Its two major aims are to assist students who are preparing for clinical immunology examinations, and to help people who want to understand more about this subject with brief and flexible sources of information. This book presents current, medically important information on the rapidly changing field of tissue typing and its relation with diseases. It includes updated information on such topics as tissue typing in medicine and transplant immunology.

HLA histocompatibility antigens. --- HL-A histocompatibility antigens --- HLA antigens --- HLA transplantation antigens --- Human leukocyte antigens --- Transplantation antigens, Human --- Histocompatibility antigens --- Major histocompatibility complex --- Immunology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.

n/a --- FOLFIRINOX --- immunofluorescence imaging --- AR-V7 --- circulating tumour cells --- chemoradioresistance --- CTC-based treatment decisions --- rVAR2 --- immunophenotyping --- immune system --- CellSearch® --- flow cytometry --- clinical trials --- circulating tumor DNA --- synaptophysin --- stem cells --- colorectal cancer --- melanoma --- CTC biology --- platelets --- AR --- CTC capture technology --- castration resistant prostate cancer (CRPC) --- PD-L1 expression --- rovalpituzumab tesirine --- HMB-45 --- thymidylate synthase --- ctDNA --- tumor cell dissemination --- solid cancers --- metastasis --- locally advanced rectal cancer --- miRNA --- epithelial-to-mesenchymal transition (EMT) --- NSCLC --- tumor biomarkers --- tumor stem cells --- circulating tumor cells --- major histocompatibility complex class I (MHCI) --- bone marrow --- heterogeneity --- cerebrospinal liquid biopsy --- fish --- glioma --- in vivo flow cytometry --- colorectal surgery --- CellSearch --- single-cell analysis --- disseminated tumor cells --- EasyCount slides --- microsatellite instability --- circulating plasma cells --- circulating leukemia cells --- ARV7 --- SLUG --- androgen receptor --- metastatic colorectal cancer --- leukocyte-derived extracellular vesicles --- prostate cancer (PCa) --- neutrophils --- liquid biopsy --- enzalutamide --- CD133 --- enrichment and detection technologies --- biomarkers --- immune checkpoint inhibitors --- biomarker --- RAD23B --- microbiome --- integrin B1 --- ACCEPT --- emboli --- small-cell lung carcinoma --- EPISPOT --- microfluidics --- early breast cancer --- circulating tumor cells (CTC) --- tumor-initiating cells (TICs) --- immunomodulation --- xenograft models --- CTC-derived xenografts --- malaria --- circulating tumor cells (CTCs) --- clinical utility --- exosomes --- liquid surgery --- ctRNA --- CTCs --- epithelial–mesenchymal transition --- targeted therapy --- hematological cells --- gene expression analysis --- hepatocellular carcinoma (HCC) --- breast cancer --- EpCAM enrichment --- prostate cancer --- CTC --- abiraterone --- fibronectin --- CTC-derived ex vivo models --- CTMat --- chromogranin A --- CTM --- exosome --- epithelial-mesenchymal transition